Methomyl MarketSize, Share & Industry Analysis, 2026-2034By Formulation TypeBy Crop TypeBy End UseBy Distribution ChannelBy Mode of Application

Methomyl is a broad-spectrum carbamate insecticide formulated as a soluble liquid concentrate, a wettable or soluble powder, and as a granular or liquid bait, used to control chewing and sucking insect pests across vegetable, fruit, field crop and cereal production. It is applied by foliar spray, soil treatment and targeted bait placement, and is also used outside crop agriculture for fly and public health pest control in livestock and municipal settings. Buyers range from commercial growers and agricultural cooperatives sourcing through agri-input dealers to public health and pest control operators procuring bait formulations directly or through distributors.

USD 315 million of revenue was recorded in the global methomyl market in 2025. By 2034 the figure reaches USD 407 million, a compound annual growth rate of 2.85% through the forecast period, along a series that runs USD 258 million in 2020, USD 305 million in 2024, USD 325 million in 2026 and USD 369 million in 2030.

Composition changes more than the total does. Others, at 4.4%, outgrows Wettable Powder (WP) at 1.64%, and its share moves from 7% to 8%. Soluble Liquid (SL) stays the largest line throughout, at USD 141.8 million in 2025 and USD 195.4 million in 2034. Soluble Liquid (SL) and Others take share over the period; Wettable Powder (WP) and Bait Formulation give it up while still growing in absolute terms.

Cut by crop type, the largest line is Vegetables: 34% of 2025 revenue, worth USD 107.1 million, and 35% at USD 142.5 million by 2034. Others (Ornamentals, Turf) grows faster at 4.67% against 3.23%, moving from 6% of revenue to 7% by 2034. Both this axis and the formulation type one divide the same revenue, which is why they are alternative views, not components.

Geographically, 38% of 2025 revenue sits in Asia Pacific (USD 119.7 million rising to USD 166.9 million) ahead of North America at 22% and USD 69.3 million. Middle East and Africa is smallest, at 7%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, four formulation type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 2.85% takes the market from USD 315 million in 2025 to USD 407 million in 2034, against 4.07% recorded over the 2020-2025 historical period.
• 45% of 2025 revenue sits in Soluble Liquid (SL) (USD 141.8 million) and it remains the largest formulation type line in 2034 at USD 195.4 million and 48%.
• Fastest growth on the formulation type axis belongs to Others: 4.4% a year, USD 22.1 million to USD 32.6 million, and a share moving from 7% to 8%.
• The bull case puts 2034 revenue at USD 448 million and the bear case at USD 366 million, either side of the USD 407 million base case, each with its own stated assumption in the full report.
• The largest region is Asia Pacific, generating USD 119.7 million in 2025 (38% of the global total) and USD 166.9 million by 2034, ahead of North America at 22%.
• China accounts for 45% of Asia Pacific in the base year, worth USD 53.9 million in 2025 and reaching USD 75.1 million by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Read across the forecast period, the global methomyl market shows movement in three places: formulation type composition, regional weight, and the 2.85% rate applied to the whole.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

Others outpaces Wettable Powder (WP). The widest spread on the formulation type axis is between Others at 4.4% and Wettable Powder (WP) at 1.64%. Over the forecast period that moves Others from 7% of revenue to 8%, and Wettable Powder (WP) from 30% to 27%. In absolute terms Others rises from USD 22.1 million to USD 32.6 million, while Wettable Powder (WP) rises from USD 94.5 million to USD 109.9 million. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 38% of revenue in 2025 to 41% in 2034, worth USD 119.7 million rising to USD 166.9 million; Latin America moves from 18% of revenue in 2025 to 21% in 2034, worth USD 56.7 million rising to USD 85.5 million; Middle East and Africa moves from 7% of revenue in 2025 to 8% in 2034, worth USD 22.1 million rising to USD 32.6 million. The offsetting side is North America at 22% moving to 20%, Europe at 15% moving to 10%, none of which contracts. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

The series never breaks trajectory. Reading the series: USD 258 million in 2020, USD 305 million in 2024, USD 315 million in 2025, USD 325 million in 2026, USD 369 million in 2030 and USD 407 million in 2034. There is no discontinuity to time, and 2.85% forecast growth against 4.07% historical means the trend continues and does not turn. That moves the planning question away from timing a turn and onto the formulation type and regional mixes, where the actual movement is.

Growth is concentrated in Others

Separate the 2.85% into its parts and three show up: an already-large base compounding, the formulation type mix moving toward its faster lines, and regional growth landing unevenly.

What holds the forecast back

Upside case: USD 448 million by 2034

The total depends on a single line

North America holds 22% of the global methomyl market in 2025, worth USD 69.3 million rising to USD 81.4 million in 2034. Among the five regions it ranks second by revenue in both years.

Share settles at 20% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The formulation type mix reported at global level applies here, with Soluble Liquid (SL) the largest line at 45% of 2025 revenue and Others the fastest-growing at 4.4%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 55.4 million in 2025 and projected to reach USD 65.1 million by 2034. At 80% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 69.3 million to USD 81.4 million over the same period, and this is the market carrying the country-level detail in the full report.

the United States buys along the same lines as the market globally; Soluble Liquid (SL) first at 45% of 2025 revenue and 48% in 2034, Others fastest at 4.4% on a share moving from 7% to 8%. Since 80% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports the United States by formulation type separately.

Methomyl is regulated in the United States as a restricted-use pesticide under the Federal Insecticide, Fungicide, and Rodenticide Act, administered by the Environmental Protection Agency. A supplier must secure product registration before sale, supporting that registration with toxicology, environmental fate, and residue data sufficient to satisfy the agency's risk assessment. Because of its acute toxicity profile, application is restricted to certified applicators, and the label must carry the signal word and handling precautions the classification requires. Tolerances for residues on treated commodities are set separately and enforced through the Federal Food, Drug, and Cosmetic Act. State-level agencies, particularly in agricultural states, layer additional registration and reporting obligations on top of the federal framework, so a supplier active nationally must track both tiers rather than treating federal clearance as sufficient on its own.

Supplier positions in the United States sit on the formulation type axis: the country buys the same lines the global market does, in the same order. Volume sits in Soluble Liquid (SL) at 45% of 2025 revenue; movement sits in Others at 4.4% growth. The full report covers country-level positioning and shares company by company; this summary does not.

4.4% of global revenue is generated in Canada; USD 13.9 million in 2025, reaching USD 16.3 million in 2034, and 20% of North America.

15% of the global methomyl market sits in Europe in 2025, worth USD 47.3 million with USD 40.7 million projected for 2034. Among the five regions it ranks fourth by revenue in both years.

Share settles at 10% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The formulation type mix reported at global level applies here, with Soluble Liquid (SL) the largest line at 45% of 2025 revenue and Others the fastest-growing at 4.4%. Per-axis and per-country detail for Europe sits in the full report.

35% of Europe's base-year revenue comes from Germany; USD 16.6 million, rising to USD 14.2 million by 2034. 35% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 47.3 million to USD 40.7 million over the same period, and this is the market carrying the country-level detail in the full report.

The formulation type pattern in Germany is the global one: 45% of 2025 revenue in Soluble Liquid (SL), 48% by 2034, against 4.4% growth in Others taking it from 7% to 8%. Since 35% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Germany by formulation type separately.

As an European Union member state, Germany applies the EU Plant Protection Products Regulation, which requires active substance approval at Union level before any formulated product reaches national authorization. Methomyl's approval status under that regime governs whether it may be placed on the German market at all, and where use is permitted, the Federal Office of Consumer Protection and Food Safety issues the national authorization alongside the Julius Kühn Institute's risk assessment role. Labelling must conform to the EU Classification, Labelling and Packaging Regulation, reflecting the substance's hazard classification for acute toxicity. Maximum residue levels are set under the EU's harmonized residue framework and enforced through routine monitoring of food and feed. A supplier must also observe restrictions tied to pollinator protection and buffer zones near water bodies, which German enforcement treats as a compliance matter.

Competition in Germany is decided on the formulation type axis rather than on geography, since suppliers here sell into the same formulation type lines reported globally. Two different problems sit on the same axis: holding Soluble Liquid (SL) at 45% of 2025 revenue, and taking Others while it grows at 4.4%. The commercial size of that position is USD 47.3 million in 2025, moving to USD 40.7 million by 2034 across the forecast period.

France is sized at USD 11.8 million in 2025, rising to USD 10.2 million by 2034; 3.7% of global revenue and 25% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

2.3% of global revenue is generated in Spain; USD 7.1 million in 2025, reaching USD 6.1 million in 2034, and 15% of Europe.

USD 119.7 million of 2025 revenue is generated in Asia Pacific, 38% of the global methomyl market rising to USD 166.9 million in 2034. Among the five regions it ranks first by revenue in both years.

41% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 2.85% global rate, so this region warrants separate treatment and should not be scaled off the total.

Within the region the formulation type split tracks the global one; 45% of 2025 revenue in Soluble Liquid (SL), fastest growth of 4.4% in Others. Per-axis and per-country detail for Asia Pacific sits in the full report.

45% of Asia Pacific's base-year revenue comes from China; USD 53.9 million, rising to USD 75.1 million by 2034. Its 45% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 119.7 million in 2025 and USD 166.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the formulation type mix reported at global level: Soluble Liquid (SL) is the largest line at 45% of 2025 revenue, moving to 48% by 2034, while Others grows fastest at 4.4% and takes its share from 7% to 8%. With 45% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports China by formulation type separately.

China regulates methomyl through its pesticide registration system administered by the Ministry of Agriculture and Rural Affairs, under which any product must obtain a formal registration certificate before manufacture or sale. Registration requires submission of toxicological and efficacy data reviewed by the Institute for the Control of Agrochemicals, and given the substance's toxicity class, supply is generally limited to licensed producers and authorized distribution channels. Labelling must follow national pesticide labelling standards, disclosing hazard classification, approved crop uses, and re-entry intervals. Residue limits on food crops are established under national food safety standards and enforced by the market regulation authority. Producers are additionally subject to production licensing and quality standards issued through China's standardization system.

China does not have a competitive structure of its own; position here is position on the formulation type axis reported above. The commercially relevant division is 45% of 2025 revenue in Soluble Liquid (SL), where the volume is, against 4.4% growth in Others, where share moves. The commercial size of that position is USD 119.7 million in 2025, moving to USD 166.9 million by 2034 across the forecast period.

10.6% of global revenue is generated in India; USD 33.5 million in 2025, reaching USD 46.7 million in 2034, and 28% of Asia Pacific.

USD 56.7 million of 2025 revenue is generated in Latin America, 18% of the global methomyl market rising to USD 85.5 million in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 21%, on growth above the market's own 2.85%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The formulation type mix reported at global level applies here, with Soluble Liquid (SL) the largest line at 45% of 2025 revenue and Others the fastest-growing at 4.4%. Per-axis and per-country detail for Latin America sits in the full report.

Brazil is the largest market within Latin America, generating USD 34 million in 2025 and projected to reach USD 51.3 million by 2034. 60% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Regional revenue of USD 56.7 million in 2025 and USD 85.5 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The formulation type pattern in Brazil is the global one: 45% of 2025 revenue in Soluble Liquid (SL), 48% by 2034, against 4.4% growth in Others taking it from 7% to 8%. With 60% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by formulation type for Brazil is reported separately in the full report.

Brazil regulates methomyl through a shared framework in which the Ministry of Agriculture, Livestock and Supply issues agronomic registration, the National Health Surveillance Agency evaluates toxicological risk, and the Brazilian Institute of Environment and Renewable Natural Resources assesses environmental impact; all three must concur before a product is registered. Given its toxicity classification, the approved label must carry the corresponding hazard pictogram and restrictions on application method and worker protection. Residue tolerances are set and published by the health surveillance agency and apply per crop use approved in the registration dossier. Distribution and sale require a licensed agronomist's prescription for the end user, a control point Brazilian regulation applies specifically to restricted-toxicity agrochemicals. Any formulation change or new crop use triggers a fresh registration review.

What separates suppliers in Brazil is where they sit on the formulation type axis, not which country they serve. Soluble Liquid (SL), at 45% of 2025 revenue, is where the volume sits, and Others, growing at 4.4%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 56.7 million in 2025, reaching USD 85.5 million by 2034 on the trajectory this study models.

4.5% of global revenue is generated in Argentina; USD 14.2 million in 2025, reaching USD 21.4 million in 2034, and 25% of Latin America.

In Middle East and Africa, 7% of global revenue puts 2025 at USD 22.1 million on the way to USD 32.6 million by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 8% by 2034, so the region grows faster than the market's 2.85% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Soluble Liquid (SL) leads here as it does globally, at 45% of 2025 revenue, and Others again grows fastest at 4.4%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

USD 7.7 million of Middle East and Africa's 2025 revenue is generated in South Africa, the region's largest market, reaching USD 11.4 million by 2034. 35% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 22.1 million in 2025 and USD 32.6 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in South Africa follows the formulation type mix reported at global level: Soluble Liquid (SL) is the largest line at 45% of 2025 revenue, moving to 48% by 2034, while Others grows fastest at 4.4% and takes its share from 7% to 8%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-formulation type revenue for South Africa appears on its own in the full report.

South Africa regulates methomyl under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, with registration administered by the Department of Agriculture, Land Reform and Rural Development through its Registrar of Act. A supplier must register the specific formulation before sale, submitting efficacy and safety data that the registrar assesses against the substance's toxicity classification. The approved label must specify handling precautions, restricted entry intervals, and permitted crop uses given that classification, and sale is typically limited to licensed agricultural retailers. Residue limits on food crops are set with reference to the registered uses and are monitored under national food safety oversight. Across much of the wider Middle East and Africa region, national registration follows a broadly similar approval-before-sale model, though the administering body and residue-setting process vary by country.

Competition in South Africa is decided on the formulation type axis rather than on geography, since suppliers here sell into the same formulation type lines reported globally. The commercially relevant division is 45% of 2025 revenue in Soluble Liquid (SL), where the volume is, against 4.4% growth in Others, where share moves. The commercial size of that position is USD 22.1 million in 2025 and USD 32.6 million by 2034, 7% of the global total in the base year.

1.7% of global revenue is generated in Saudi Arabia; USD 5.5 million in 2025, reaching USD 8.2 million in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Formulation Type, Crop Type, End Use, Distribution Channel, Mode of Application, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.